BSc · MBBS · PGDip (Oncology) · MRCP · FRCR · MD
Radiotherapy and systemic therapy for urological and gynaecological cancers, in both the radical and palliative settings.
Clinical Lead for Brachytherapy at Mount Vernon Cancer Centre. Low dose radiotherapy for benign conditions.
Dr Mohammed Abdul-latif is a Consultant Clinical Oncologist treating urological and gynaecological cancers with radiotherapy and systemic therapy, in both the curative and palliative settings. At Mount Vernon Cancer Centre he is also Clinical Lead for brachytherapy, and he offers low dose radiotherapy for a range of benign conditions.
The core of his practice is the day-to-day oncological care of patients with prostate, bladder, cervical, endometrial, vaginal and vulval cancers — from first diagnosis and treatment planning through to follow-up. He delivers radical (curative) radiotherapy using modern external beam techniques including IMRT, VMAT, image-guided radiotherapy and stereotactic ablative radiotherapy (SABR/SBRT), alone or alongside chemotherapy or hormone therapy, and hydrogel spacer (SpaceOAR) insertion forms a routine part of his prostate radiotherapy pathway.
Palliative care is an equally important part of his work. Short courses of palliative radiotherapy can relieve pain from bone metastases, control bleeding and ease pressure symptoms, and he is closely involved in the urgent management of metastatic spinal cord compression at Mount Vernon. He also prescribes and manages systemic anti-cancer treatment — chemotherapy, immunotherapy and targeted therapies — with curative or palliative intent, including concurrent chemoradiotherapy.
Brachytherapy places a radiation source directly within or immediately adjacent to a tumour, allowing a very high dose to be delivered to the target while sparing surrounding healthy tissue. Complex brachytherapy takes this further, using image-guided placement of interstitial needles and catheters into the tumour itself, with the implant designed around each patient's individual anatomy.
Dr Abdul-latif undertakes complex delivery for gynaecological, urological, oesophageal and rectal cancers, including contact radiotherapy, and performs interstitial implants for rarer presentations involving the skin, breast and soft tissues — including a dedicated breast brachytherapy programme for women whose cancer has recurred after previous radiotherapy. Techniques of this kind remain available in only a small number of UK centres. More about the brachytherapy service →
He also offers low dose radiotherapy (LDRT) — a gentle, outpatient treatment using very small doses of radiation to reduce inflammation and pain in conditions such as osteoarthritis, plantar fasciitis, tennis elbow and Achilles tendinopathy, to slow early Dupuytren's and Ledderhose disease, and to prevent heterotopic ossification after hip surgery, where standard treatments have not helped. More about low dose radiotherapy →
Dr Abdul-latif qualified from Imperial College School of Medicine in 2013, finishing in the top decile of his year, and trained across North London hospitals in general medicine before specialising in clinical oncology. He holds a Postgraduate Diploma (PGDip) in Oncology and a Doctorate of Medicine (MD) from the University of Manchester, completed under the supervision of Professor Peter Hoskin, with a thesis on the role of functional MRI in cervical cancer. He publishes regularly and presents at international meetings including ESTRO. He was awarded the Royal College of Radiologists' Kay-Durrant Fellowship, which took him to France and Italy for further training in breast, rectal and head and neck brachytherapy.
He is an Honorary Senior Lecturer at Brunel Medical School, a role that recognises a substantial ongoing contribution to university teaching alongside clinical practice. It involves the delivery and design of undergraduate oncology teaching, supervision and assessment of medical students during their clinical placements, examining, and the supervision of student research projects, as well as supporting the school's wider academic and curriculum development.
He speaks English and Arabic. He is recognised by all major private health insurers, including as a Bupa Platinum, Fee Assured consultant. He also holds an Education Fellowship at the Institute of Cancer Research and is Module Lead for Oncology for Brunel Medical School students at Mount Vernon Cancer Centre.
Dr Abdul-Latif's practice combines routine radical and palliative oncology — radiotherapy and systemic therapy for urological and gynaecological cancers — with specific technical expertise in brachytherapy, and low dose radiotherapy for benign conditions.
Assessment, treatment planning and follow-up for prostate, bladder, penile, cervical, endometrial, vaginal and vulval cancers — with radical and palliative intent, coordinated through the specialist multidisciplinary team.
Curative external beam radiotherapy using IMRT, VMAT, IGRT and SABR/SBRT, with SpaceOAR for prostate cancer. Palliative radiotherapy for pain, bleeding and spinal metastases, including metastatic spinal cord compression.
Chemotherapy, immunotherapy, targeted and hormone therapies across urological and gynaecological cancers — in both curative and palliative settings, including concurrent chemoradiotherapy.
Clinical Lead at Mount Vernon Cancer Centre. Gynaecological, urological, rectal, oesophageal, breast, skin and soft tissue brachytherapy — including salvage, re-irradiation and organ-preservation approaches.
View the brachytherapy service →Gentle outpatient treatment for painful osteoarthritis, plantar fasciitis, tennis elbow and Achilles tendinopathy, early Dupuytren's and Ledderhose disease, and prevention of heterotopic ossification after hip surgery.
View low dose radiotherapy →Management of pelvic radiation disease in both the acute and chronic phase — a clinically important area for patients who have undergone pelvic radiotherapy, and a specific research and clinical interest.
Signature Practice
Image-guided interstitial needle and catheter implants designed around each patient's anatomy, for gynaecological, urological, oesophageal, rectal, skin, soft tissue and breast disease — including salvage and re-irradiation approaches for patients where standard options have been exhausted.
Salvage and re-irradiation brachytherapy — including breast-conserving approaches to avoid mastectomy, and rectal-preserving approaches to avoid a stoma — is an area requiring highly specialised training and experience, and represents an alternative for patients where standard options have been exhausted. Read more →
A full range of external beam radiotherapy, systemic therapy and brachytherapy for urological and gynaecological cancers and beyond, offered with radical or palliative intent as appropriate — alongside low dose radiotherapy for benign conditions.
Brachytherapy service →
Low dose radiotherapy →
Curative external beam radiotherapy for prostate, bladder, cervical, endometrial, vaginal and vulval cancers, given alone, after surgery, or with concurrent chemotherapy or hormone therapy. Intensity-Modulated Radiotherapy (IMRT), Volumetric Modulated Arc Therapy (VMAT), image guidance (IGRT) and Stereotactic Ablative Body Radiotherapy (SABR/SBRT), with SpaceOAR hydrogel spacer for prostate cancer.
Short, well-tolerated courses of radiotherapy to relieve symptoms and improve quality of life in advanced cancer — including pain from bone metastases, bleeding, and pressure symptoms. Stereotactic treatment for spinal and oligometastatic disease where appropriate, and urgent radiotherapy for metastatic spinal cord compression.
Systemic anti-cancer therapies across urological and gynaecological cancers, given with curative or palliative intent — including concurrent chemoradiotherapy, treatment for advanced and metastatic disease, and hormone therapy for prostate cancer. Manages patients on a range of agents from chemotherapy to immunotherapy and targeted therapies.
Very low doses of radiation to calm inflammation and reduce pain in conditions that have not responded to standard treatment — osteoarthritis, plantar fasciitis, tennis elbow and Achilles tendinopathy — to slow early Dupuytren's and Ledderhose disease, and to prevent heterotopic ossification after hip surgery. Short, painless outpatient courses.
Read more →Intracavitary and interstitial brachytherapy for cervical, endometrial, vaginal and vulval cancers. MRI-guided adaptive planning. Includes salvage and re-irradiation brachytherapy for recurrent gynaecological malignancy.
Read more →High-dose-rate (HDR) prostate brachytherapy as monotherapy or boost, and permanent seed implant (LDR). SpaceOAR hydrogel spacer insertion to protect the rectum. Includes focal salvage HDR brachytherapy for locally relapsed prostate cancer.
Read more →Contact radiotherapy and interstitial brachytherapy for rectal and oesophageal cancers. Includes organ-preserving brachytherapy for rectal cancer and re-irradiation of recurrent disease to avoid surgical resection.
Read more →Multicatheter interstitial brachytherapy allows a second course of radiotherapy to the tumour bed alone after previous breast radiotherapy, making breast conservation a possible alternative to mastectomy in the salvage setting for selected patients. Also offered for accelerated partial breast irradiation and palliative indications.
Read more →Interstitial and surface-mould brachytherapy for skin cancers and soft tissue tumours, including rarer presentations and sites where surgery would be disfiguring or where previous radiotherapy limits further external beam treatment.
Read more →Dr Abdul-Latif publishes regularly and has presented as first author at multiple ESTRO congresses and other international meetings. His research covers brachytherapy, functional imaging in cervical cancer, stereotactic radiotherapy, systemic therapies and immunotherapy, and radiation-related toxicity.
View full publication list on Google ScholarPeer-reviewed publications
BMJ Oncology, 2025 — Abdul-Latif M, Conibear J, Thiruthaneeswaran N, Tsang YM. PMID 40135242
Brachytherapy, 2024; 23(3): 335–341 — Abdul-Latif M, Gal J, Schiappa R, Rizzi Y, Gautier M, Hannoun-Levi JM. PMID 38383205
BMJ Open, 2024; 14(4): e077390 — Abdul-Latif M, Choudhury A, Tharmalingam H et al.
Clinical Oncology, 2024 — Armstrong S, Makris A, Belessiotis-Richards K, Abdul-Latif M et al.
Doctoral thesis (MD), University of Manchester — Abdul-Latif M
Clinical Oncology, 2023; 35(9): 598–610 — Abdul-Latif M, Tharmalingam H, Tsang Y, Hoskin PJ. PMID 37246040
Clinical Oncology, 2023 — Sherriff J, Abdul-Latif M, Tsang YM. PMID 36710152
Cancer Treatment Reviews, 2020 — Abdul-Latif M et al. PMID 32505807
Clinical Oncology, 2019; 31(2) — Abdul-Latif M et al.
Selected conference abstracts
ESTRO 2024 — Radiotherapy and Oncology 194: S151–S153 — Abdul-Latif M, Gal J, Schiappa R, Gautier M, Rizzi Y, Hannoun-Levi JM
International Journal of Gynecological Cancer 34: A280 — Gupta N, Tharmalingam H, Hoskin P, Abdul-Latif M
ASCO 2020 — Journal of Clinical Oncology 38(15 suppl): 10070 — Storey L, Abdul-Latif M, Kreft S et al.
Research Focus
Brachytherapy outcomes across gynaecological, urological, GI and breast cancers. Multiple first-author proffered papers at ESTRO, including salvage brachytherapy and functional MRI.Doctoral Research
Functional MRI of the cervix during chemoradiotherapy — MD(Res) awarded by the University of Manchester under Professor Peter Hoskin, 2025.Pelvic Radiation Disease
Management of radiation-related complications in the acute and chronic phase — an under-recognised area of oncological care that Dr Abdul-Latif is actively researching and improving.Hal Gray Unit · NHS and private practice
Circle Health Group · private practice
Remote appointments UK-wide and international
Fees may vary. Please contact the secretary to confirm before booking.
Video and telephone consultations also available.
Self-pay patients welcome. All major insurers accepted.
Recognised Insurers
Dr Abdul-Latif holds Bupa Platinum status and is Fee Assured — Bupa patients do not incur excess charges on his consultations.
For appointments, referrals, or general enquiries, please contact Dr Abdul-Latif's medical secretary. Self-pay and all major insurers are accepted.
Medical Secretary
Amy Bignell
